We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Ulcerative colitis specialist Sublimity Therapeutics brought on Jesse Hall, M.D., to be its new chief medical officer, as the company looks to advance the clinical development of its lead candidate into a phase 2b study.